TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:30
Apollomics Inc. ( APLM )
10.49USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-88.71%
APLM
SPY
32.66%
-98.94%
APLM
SPY
108.59%
APLM
0.00%
SPY
302.52%
APLM
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
983.33
957.40
0.06
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-17.22
433.57
47.26
-1.79
0.00
-19.06
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-1299.43
100.00
-1297.62
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-120.85
-94.93
0.00
Other Earnings and Cash Flow Stats:
Apollomics Inc. ( APLM ) Net Income TTM ($MM) is -57.11
Apollomics Inc. ( APLM ) Operating Income TTM ($MM) is -53.01
Apollomics Inc. ( APLM ) Owners' Earnings Annual ($MM) is 0.00
Apollomics Inc. ( APLM ) Current Price to Owners' Earnings ratio is 0.00
Apollomics Inc. ( APLM ) EBITDA TTM ($MM) is -52.93
Apollomics Inc. ( APLM ) EBITDA Margin is -1297.62%
Capital Allocation:
Apollomics Inc. ( APLM ) has paid 0.00 dividends per share and bought back -3.918 million shares in the past 12 months
Apollomics Inc. ( APLM ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Apollomics Inc. ( APLM ) Interest-bearing Debt ($MM) as of last quarter is 0
Apollomics Inc. ( APLM ) Annual Working Capital Investments ($MM) are 5
Apollomics Inc. ( APLM ) Book Value ($MM) as of last quarter is 20
Apollomics Inc. ( APLM ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Apollomics Inc. ( APLM ) has 25 million in cash on hand as of last quarter
Apollomics Inc. ( APLM ) has 12 million of liabilities due within 12 months, and long term debt 4 as of last quarter
Apollomics Inc. ( APLM ) has 93 common shares outstanding as of last quarter
Apollomics Inc. ( APLM ) has 0 million USD of preferred stock value
Academic Scores:
Apollomics Inc. ( APLM ) Altman Z-Score is 11.09 as of last quarter
Apollomics Inc. ( APLM ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Apollomics Inc. ( APLM ) largest shareholder is Goldman Sachs Group Inc owning 13799 shares at 0.14 ($MM) value
(an insider) shares of Apollomics Inc. ( APLM ) for the amount of $ on
47.32% of Apollomics Inc. ( APLM ) is held by insiders, and 2.09% is held by institutions
Apollomics Inc. ( APLM ) went public on 2021-11-26
Other Apollomics Inc. ( APLM ) financial metrics:
FCF:-34.83
Unlevered Free Cash Flow:-59.99
EPS:-0.01
Operating Margin:-1299.43
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-338.41
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Apollomics Inc. ( APLM ) :
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.